GLP-1 Prescriptions for People With No Medical Need Are Climbing
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"GLP-1 Prescriptions for People With No Medical Need Are Climbing" is generating significant coverage in the Health category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Forbes and Newser. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 43d ago.
Quick answers
Why is "GLP-1 Prescriptions for People With No Medical Need Are Climbing" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- More Than 1 Million People Use GLP-1s Without Medical Need—Know The Risks Forbes · 49d ago
- Off-Label Use Surges in a 'Big Ozempic Experiment' Newser · 49d ago
Topics
Related trends
Dog's Odd Behavior Alerts Mom to Baby's Hidden Heart Issue
A family Doberman's persistent crying alerted a mother to a hidden heart issue in her infant child.
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
Hers Health, Inc. Reports Third Quarter 2026 Financial Results
Hims & Hers Health reported Q3 2026 revenue of $401.6 million, up 69% year over year, but narrowed its full-year revenue guidance and cut its adjusted EBITDA forecast, sending shares down sharply.
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
Federal regulators issue a new warning regarding GLP-1 medications and a rare eye condition linked to sudden blindness.
US regulator orders makers of weight-loss drugs to carry blindness risk warning
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.